BioCentury
ARTICLE | Clinical News

FDA approves Shire's Takhzyro, first mAb to prevent HAE

August 31, 2018 6:41 PM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) said FDA approved Takhzyro lanadelumab-flyo to prevent attacks of hereditary angioedema in patients ages 12 and older. The company said Takhzyro is the first mAb approved in the U.S. to prevent the disease.

Shire obtained Takhzyro via its 2016 acquisition of Dyax Corp. Under the terms of the acquisition, Dyax shareholders are eligible to receive a contingent value right (CVR) worth $646 million tied to the drug's U.S. approval (see "Shire HAE Treatment from Dyax Deal Clears Phase III Hurdle")...

BCIQ Company Profiles

Dyax Corp.

Shire plc

BCIQ Target Profiles

Plasma kallikrein (KLKB1)